Literature DB >> 2495187

Stimulation of lymphocyte migration by endotoxin, tumor necrosis factor, and interferon.

T B Issekutz1, J M Stoltz.   

Abstract

Since several studies have demonstrated that lipopolysaccharide (LPS), tumor necrosis factor (TNF), and interleukin-1 (IL-1) enhanced lymphocyte binding to endothelial cells in vitro, we examined the effects of these agents on lymphocyte migration in vivo. Small peritoneal exudate lymphocytes (sPEL), which perferentially migrate into inflammatory sites, were radiolabeled with 111In and injected iv into rats. The id injection of LPS was a strong stimulus for the migration of these cells into the skin. TNF alpha was also a good stimulator of lymphocyte migration, while TNF beta and IL-1 alpha were weak or nearly inactive. Kinetic analysis demonstrated that migration to TNF was rapid, with a peak at 6 hr, followed by a steady decline, while migration to LPS was sustained for 24 hr. TNF alpha, TNF beta, and IL-1 alpha, when combined with interferon-gamma (IFN-gamma) or IFN-alpha/beta produced striking synergistic increases in lymphocyte migration. Combinations of the TNFs and IL-1 had less than additive effects, as did combinations of the IFNs. Qualitatively similar migration responses were found when spleen T cells instead of sPEL were studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495187     DOI: 10.1016/0008-8749(89)90184-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Tumour necrosis factor-alpha stimulates invasiveness of T-cell hybridomas and cytotoxic T-cell clones by a pertussis toxin-insensitive mechanism.

Authors:  G La Rivière; J W Klein Gebbinck; C A Schipper; E Roos
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Re-evaluation of the chemotactic activity of tumour necrosis factor for monocytes.

Authors:  J M Wang; S Walter; A Mantovani
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  Peripheral blood lymphopenia in gangrenous appendicitis.

Authors:  M Jahangiri; J H Wyllie
Journal:  BMJ       Date:  1990-07-28

4.  Dual inhibition of VLA-4 and LFA-1 maximally inhibits cutaneous delayed-type hypersensitivity-induced inflammation.

Authors:  T B Issekutz
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

5.  The effect of cytokines and chemotactic agonists on the migration of T lymphocytes into skin.

Authors:  I G Colditz; D L Watson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

6.  Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury.

Authors:  Jiqiu Chen; Elie Chemaly; Lifan Liang; Changwon Kho; Ahyoung Lee; Jaeho Park; Perry Altman; Alison D Schecter; Roger J Hajjar; Sima T Tarzami
Journal:  Am J Pathol       Date:  2010-02-04       Impact factor: 4.307

7.  Cell migration studies in the adoptive transfer of adjuvant arthritis in the Lewis rat.

Authors:  A G Van de Langerijt; S G Volsen; C A Hicks; P J Craig; M E Billingham; W B Van den Berg
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

8.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

9.  An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues.

Authors:  Ronjon Chakraverty; Daniel Côté; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Teviah Sachs; Costas M Pitsillides; Roderick Bronson; Terry Means; Charles Lin; Megan Sykes
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

10.  Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma.

Authors:  J L Baron; J A Madri; N H Ruddle; G Hashim; C A Janeway
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.